Radnostix Reports 6% Revenue Drop, Swings to $0.91M Net Loss in 10-K
INIS has more than doubled off its 52-week low of $0.035 on light trading volume (0.1× avg).
Summary
Radnostix Inc. reported a significant deterioration in its annual financial performance, with total revenues declining 6% year-over-year to $13.07 million. The company swung from a net income of $8,574 in the prior year to a net loss of $0.91 million for the year ended December 31, 2025, as detailed in its 10-K filing. Additionally, the gross profit margin decreased from 62% to 59%. These results indicate material operational challenges, including declines in theranostics and cobalt product lines due to supply outages, which could negatively impact investor sentiment and the stock price. Traders will be closely watching for management's strategy to address the revenue contraction and return to profitability, as well as the progress of new medical device launches planned for 2026.
At the time of this announcement, INIS was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $43.5M. The 52-week trading range was $0.03 to $0.11. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Wiseek News.